Quick Answer
Lucid Diagnostics Inc. reported Net Income Loss of -$58.01 million for the year ending 2025.
- Lucid Diagnostics Inc. showed a decrease of -27.4% in Net Income Loss from 2024 to 2025.
- This data is from Lucid Diagnostics Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$2.02 million | Q1 2021: -$3.65 million | Q2 2021: -$6.16 million | Q3 2021: -$6.96 million | Q1 2022: -$12.27 million | Q2 2022: -$14.62 million | Q3 2022: -$14.35 million | Q1 2023: -$16.25 million | Q2 2023: -$11.38 million | Q3 2023: -$14.21 million | Q1 2024: -$10.61 million | Q2 2024: -$11.01 million | Q3 2024: -$12.37 million | Q1 2025: -$26.91 million | Q2 2025: -$4.44 million | Q3 2025: -$10.40 million.
- Over the full 6 years of available data (2020 to 2025), Lucid Diagnostics Inc.'s Net Income Loss has declined by 600.6%.
- Historical annual values: Fiscal year 2025: -$58.01 million | Fiscal year 2024: -$45.53 million | Fiscal year 2023: -$52.67 million | Fiscal year 2022: -$56.17 million | Fiscal year 2021: -$28.08 million | Fiscal year 2020: -$8.28 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: